CENTER FOR NEUROLOGICAL DISORDERS, S.C.
What is Myasthenia Gravis (MG)?
Myasthenia Gravis (MG) is a chronic autoimmune neurological condition that causes muscle weakness and fatigue. It occurs when the immune system interferes with communication between the nerves and muscles, making it harder for muscles to respond normally.
Symptoms can vary from person to person and may include drooping eyelids, double vision, difficulty speaking or swallowing, weakness in the arms or legs, and shortness of breath. A common feature of MG is that muscle weakness may worsen with activity and improve with rest.
While there is currently no cure for MG, effective treatments are available to help manage symptoms, improve muscle strength, and support quality of life. Treatment is individualized based on each patient's symptoms and needs.
1
argenx PASS (Post-Authorization Safety Study) of efgartigimod alfa (VYVGART or VYVGART HYTRULO) in Generalized Myasthenia Gravis
This is an observational study (not testing a new treatment vs placebo), designed to monitor how people with generalized myasthenia gravis (gMG) fare when prescribed efgartigimod (brand name: VYVGART or VYVGART HYTRULO) under real-world conditions. It compares outcomes in patients who receive efgartigimod at the start or soon after enrollment with those who do not receive it. The goal is to collect safety data and understand its use in routine care. (NCT06298565)
2
Argenx ARGX-113-2407 – An Open-label Study of Vyvgart Hytrulo in New-Onset Generalized Myasthenia Gravis
This Phase 4 study is evaluating Vyvgart Hytrulo (efgartigimod PH20 SC) in adults who have been recently diagnosed with generalized myasthenia gravis (gMG). The study will evaluate how treatment affects myasthenia gravis symptoms, daily functioning, and quality of life over approximately one year. (NCT06909214)
3
MyClad: MS700568_0183 - Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis
This Phase 3 study is evaluating a new oral formulation of cladribine in adults with generalized myasthenia gravis. Participants receive either cladribine or placebo during the initial study period, followed by longer-term follow-up to evaluate effectiveness, safety, and whether additional treatment may be needed. (NCT06463587)
4
RemeMG - A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis
RemeMG is a phase III trial studying telitacicept, an injectable biologic drug, in people with generalized myasthenia gravis who test positive for certain autoantibodies. The first 24 weeks of the study are double-blind and placebo-controlled, meaning neither the participants nor the researchers know who is receiving the drug. After that, everyone can receive telitacicept in an open-label extension phase. The main aim is to see whether telitacicept can effectively reduce gMG symptoms and to monitor for any side effects over time. (NCT06456580)
5
MG0038 – A study evaluating efficacy and safety of RYSTIGGO (rozanolixizumab) in study participants with oMG
This Phase 3 study is evaluating rozanolixizumab in adults with ocular myasthenia gravis. The study is designed to compare rozanolixizumab with placebo to evaluate its effectiveness, safety, and tolerability in people with ocular symptoms of myasthenia gravis. (NCT07463521)
Get in Touch
Email: Research@cndmilwaukee.com
Phone: 414-214-7275